ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Jun Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-7008-4876; OpenAlex author ID A5100384946. Sources: OpenAlex.

Their work

Papers: 5 (first author 2, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 22

Papers, trials and grants by year

2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 5

Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. Co-author DOI 10.1016/j.canlet.2026.218558 ↗
SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936 ↗
Trends in pancreatic cancer incidence, prevalence, and survival outcomes by histological subtypes: a retrospective cohort study. Last author DOI 10.1093/gastro/goaf030 ↗
Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. First author DOI 10.1016/j.canlet.2023.216423 ↗
Epidemiology of pancreatic cancer: New version, new vision. First author DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jinxin Tao · 3 shared papers, 2023–2025 · strength 0.53
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Yueze Liu · 3 shared papers, 2023–2025 · strength 0.53
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Jiangdong Qiu · 3 shared papers, 2023–2025 · strength 0.53
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Taiping Zhang · 3 shared papers, 2023–2025 · strength 0.53
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Lei You · 2 shared papers, 2023–2026 · strength 0.40
- Paper Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. DOI 10.1016/j.canlet.2026.218558 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Wenhao Luo · 2 shared papers, 2023–2025 · strength 0.37
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
Yize Mao · 1 shared paper, 2025 · strength 0.33
- Paper Trends in pancreatic cancer incidence, prevalence, and survival outcomes by histological subtypes: a retrospective coho… DOI 10.1093/gastro/goaf030 ↗
Qiuxia Yang · 1 shared paper, 2025 · strength 0.33
- Paper Trends in pancreatic cancer incidence, prevalence, and survival outcomes by histological subtypes: a retrospective coho… DOI 10.1093/gastro/goaf030 ↗
Sen Lei · 1 shared paper, 2025 · strength 0.33
- Paper Trends in pancreatic cancer incidence, prevalence, and survival outcomes by histological subtypes: a retrospective coho… DOI 10.1093/gastro/goaf030 ↗
Dan Su · 2 shared papers, 2023 · strength 0.33
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Ruobing Wang · 2 shared papers, 2023 · strength 0.33
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗
Gang Yang · 1 shared paper, 2026 · strength 0.24
- Paper Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. DOI 10.1016/j.canlet.2026.218558 ↗
Yupei Zhao · 1 shared paper, 2026 · strength 0.24
- Paper Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. DOI 10.1016/j.canlet.2026.218558 ↗
Zhe Cao · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Tao Liu · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Jianchun Xiao · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Hao Chen · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Hua Huang · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Yifan Fu · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Yuanyang Wang · 1 shared paper, 2025 · strength 0.20
- Paper SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocar… DOI 10.1002/mc.23936 ↗
Haowei Ma · 1 shared paper, 2023 · strength 0.17
- Paper Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. DOI 10.1016/j.canlet.2023.216423 ↗
Wenhao Luo · 1 shared paper, 2023 · strength 0.16
- Paper Epidemiology of pancreatic cancer: New version, new vision. DOI 10.21147/j.issn.1000-9604.2023.05.03 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.